157 related articles for article (PubMed ID: 32712436)
21. Cell Cycle Regulation and Melanoma.
Xu W; McArthur G
Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
[TBL] [Abstract][Full Text] [Related]
22. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
23. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
24. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.
Murphy JM; Jeong K; Ahn EE; Lim SS
J Biol Chem; 2022 Jun; 298(6):102013. PubMed ID: 35525274
[TBL] [Abstract][Full Text] [Related]
25. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
26. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
27. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
30. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
31. [Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].
Qin Q; Ren Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):176-181. PubMed ID: 32102134
[TBL] [Abstract][Full Text] [Related]
32. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
33. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract][Full Text] [Related]
34. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
36. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
Guan H; Du Y; Han W; Shen J; Li Q
Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
[TBL] [Abstract][Full Text] [Related]
37. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
Maelandsmo GM; Flørenes VA; Hovig E; Oyjord T; Engebraaten O; Holm R; Børresen AL; Fodstad O
Br J Cancer; 1996 Apr; 73(8):909-16. PubMed ID: 8611425
[TBL] [Abstract][Full Text] [Related]
38. Cell cycle control as a promising target in melanoma.
Lee B; Sandhu S; McArthur G
Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
[TBL] [Abstract][Full Text] [Related]
39. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
40. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
